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Autotaxin (ATX) is an extracellular lysophospholipaseD (lysoPLD) released from normalcells and cancer cells. Activity of ATX is
detected in various biological ﬂuids. The lysophosphatidic acid (LPA) is the main product of ATX. LPA acting through speciﬁc G
protein-coupled receptors (LPA1-LPA6)a ﬀects immunological response, normal development, and malignant tumors’ formation
and progression. In this review, the impact of autotoxin on biology of melanoma cells and potential treatment is discussed.
1.Biochemistry and Structureof Autotoxin
Autotaxin, ATX (E.C. 3.1.4.39), is a member of the family of
nucleotide pyrophosphatases/phosphodiesterase (NPP1-7)
and is also referred, as NPP2 [1]. It is to a glycoprotein
with four possible N-glycosylation sites, synthesized as a pre-
proenzyme and is secreted to extracellular space following
two N-terminal cleavages (27 and 8 amino acids) [2, 3].
ATX is a constitutively active enzyme possessing activity
of phospholipase D. It hydrolyzes the head groups of ly-
sophospholipids to lysophosphatidic acid (1 or 2-acyl-
sn-glycerol-3-phosphate, LPA) and also acts on sphingo-
sylphosphorylcholine to produce sphingosine 1-phosphate
(S1P) [4, 5]. Both, LPA and S1P are strong inhibitors
of ATX with aﬃnity to enzyme approximately 1000-fold
higher than reported for ATX substrates [6]. mRNA for
ATX has been detected in brain, ovary, lung intestine, and
kidney but enzyme activity has been detected in blood,
cerebrospinal and seminal ﬂuid, urine, and saliva [7–11]. It
is not ﬁltered in the glomerulus because of high molecular
weight (∼125kDa) but is cleared from the circulation by the
scavenger receptors of liver sinusoidal endothelial cells [12].
Moreover, ATX is the main source of blood LPA (∼0.1μM
plasma and ∼1μMs e r u m ) ,h o w e v e r ,n o tf o rS 1 P[ 13, 14].
There is evidence that S1P is produced intracellularly via
sphingosine kinases and transported through ATP-binding
cassette transporter [15, 16]. ATX hydrolyzes also ATP;
however, aﬃnity to ATP is at least 50-fold lower then
for lysophospholipids [17, 18]. LPA acts on target cells
through speciﬁc G-protein-coupled receptors: LPA1/Edg2,
LPA2/Edg4, LPA3/Edg7, LPA4/GPR23/P2Y9,L P A 5/GPR92,
LPA6/P2Y5 broadly expressed in normal and cancer cells
[19, 20]. The LPA-binding proteins for example, albumin,
determine the activation of the speciﬁc LPA receptors; LPA3,
in contrast to LPA1 and LPA2, is not activated by complex
LPA-albumin [21].
The structure of autotoxin is presented in Figure 1.A t
the N-terminus, ATX possesses hydrophobic signal sequence
(SS) followed by two somatomedin B-like domains (SBLD)
with RGD tripeptide motif suggesting that this domain
may play a role in cell-extracellular matrix interactions.
At catalytic domain (CD), Thr210 and N542-linked glycan
are suggested to be responsible for hydrolytic activity of
ATX, but motif G/FXGXXG is responsible for metal binding.
A T Xa c t i v i t yi ss t i m u l a t e db yd i v a l e n tc a t i o n sf o re x a m p l e ,
Ca2+,M g 2+,a n dC o 2+.C - t e r m i n a l l yt oC Di st h en u c l e a s e -
like domain (NLD). It contains EF-hand-like motif and is
structurally similar to DNA and RNA-nonspeciﬁc endonu-
cleases; however, it lacks the catalytic activity. In humans,
NLD is covalently linked with catalytic domain via disulﬁde2 Enzyme Research
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Figure 1: Scheme of the structure domains of autotaxin isoforms.
SS: signal sequence, SBLD: somatomedin B-like domains, CD:
catalytic domain, NLD: nuclease-like domain.
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Figure 2:RoleofATX-LPA axisinmotilityofmelanomacells.ATX:
autotaxin,LPA:lysophosphatidicacid,andLPC:lysophospholipids.
bridge (C413-C805). The ATX gene is located on chromo-
some 8 at position 8q24.1 and ATX has three alternative
splicing isoforms in humans: ATX teratocarcinoma-derived
ATX-t (925 a.a); melanoma-derived ATX-m (863 a.a), and
brain speciﬁc, ATX-γ (888 a.a) [22–25].
2. RoleofAutotoxinduring
Normal Development
ATX has a critical role in formation of vasculature by vas-
culogenesis and angiogenesis. ATX knockout mice (atx−/−)
are lethal around embryonic day 10.5. Admittedly, ATX
is a major producing enzyme for LPA, nevertheless the
phenotypes of LPA receptors knockout mice is less severe,
suggesting that ATX-induced cellular signal may involve
others pathways. This speculation is supported by results of
experiments where modiﬁcation of LPA level in blood (2-
fold increase) by driving ATX expression is not suﬃcient to
induce tumorigenesis [13, 26–28].
3.RoleofAutotoxininBiology of
Melanoma Cells
ATXwasidentiﬁedin theculturedcellsupernatant ofhuman
melanoma cells (A2058) as a cell motility-stimulating factor
acting at pM-nM concentrations in pertussis toxin-sensitive
manner [29]. Further studies have provided evidence that
LPA, product of ATX, mediates chemotaxis and proliferation
of melanoma cells [30]. The recent experiments suggest
that ATX expression is one of the factors involved in
metastasis of melanoma cells (Figure 2). Inhibition of ATX
production blocks LPA-induced migration of melanoma
cells [31]. It has been detected that melanoma metastatic
specimens have increased ATX level, and ATX expression in
primary melanoma is higher than in melanoma in situ [32].
Moreover, reduced expression of ATX predicts survival in
uveal melanoma [33].
It has been shown that ATX-stimulated motility is
suppressed by an LPA1-selective antagonist, Ki16425, in
melanoma cells [34]. Accumulating evidence suggest the
various intracellular signaling pathways may be involved
in ATX-induced motility of melanoma cell. It has been
shown that this action is mediated through G-protein
coupled isoform of phosphatidylinositol 3-kinase γ (PI3Kγ)
suggesting involvement of proteins located downstream of
PI3Kγ,forexample,small Gproteins[35]. Accordingly,there
is evidence that ATX induces Cdc42/Rac1/p21-activated
kinase (PAK1) complex formation [36]. The experimental
data suggest that this complex is required for LPA-induced
activation of focal adhesion kinase (FAK) [37]. The changes
of PAK1 and FAK activity aﬀect cytoskeleton proteins and
structural integrity of melanoma cells. Moreover, ATX in
melanoma cells induces the expression and activity of
urokinase-type plasminogen activator (UPA) in a dose-
dependent manner. This action is mediated by Gi proteins
and PI3K/Akt signaling involving translocation of p65 into
the nucleus and DNA binding of necrosis factor kappa B
[38]. In general, action of LPA on melanoma cells enhances
theirmetastaic potential(Figure 3).Recent experiments have
provided evidence about the role of LPA receptors in biology
of melanoma cells [32]. Downregulation of LPA3 and using
sequence-speciﬁc small interfering RNA (siRNA) reduces
melanoma cells viability and proliferation. The eﬀects of
LPA receptors activation in melanoma cells are presented in
Figure 4.
4. Autotoxinas a PharmacologicalTarget
The approved melanoma therapy lacks signiﬁcant eﬃciency,
hence, new therapeutic targets are under investigation. The
current research focuses on the autotoxin-LPA axis [39].
Because LPA acts on multiple receptors with overlapping
activities, currently the LPA receptors are not attractive as
a pharmacological target, and the main stream of investiga-
tion concerns ATX activity.
4.1. L-Histidine. L-histidine inhibits activities of ATX in
a non-competitive manner with IC50 ∼ 4mM and A TX-
stimulated migration of human melanoma cells; 10mM
L-histidine induces90%–95%reductioninstimulatedmotil-
ity. The proposed mechanism of L-histidine action is based
on inhibition of a process that is required for the hydrolysis
of both nucleotides and phospholipids [40].
4.2. Analogs of Bioactive Lipids. ATX is negatively regulated
by LPA. The eﬀect is dependent on the length of the
acyl chain; maximal inhibition is induced by 1-oleoyl-LPA
(IC50 ∼ 0.1–2μM), 1-palmitoyl-LPA, and 1-myristoyl-LPA
whereas short-chain LPA (6:0) has no measurable eﬀect.
The inhibition of ATX activity results from a combinationEnzyme Research 3
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Figure 3: A proposal role for LPA receptors during melanoma
progression. LPA receptors activation in melanoma cells leads
to p21-activated kinase (PAK) and focal adhesion kinase (FAK)
and to the activation of phosphoinositide 3-kinase/Akt-kinase
and urokinase-type plasminogen activator (UPA). Finally, the
melanoma cells express the metastatic phenotype.
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Figure 4: The LPA1 and LPA3 receptors as a potential target for
pharmacologicalintervention.
of a decreased turnover number and decreased aﬃnity of the
active site for its substrates. Of note, LPA both inhibits ATX
and activates LPA receptors (EC50 for LPA 18:1 at LPA1−4 ∼
0.007–0.5μM), therefore it may induce the opposite of the
intended eﬀect [6, 41].
The othergroupofATXinhibitorsare analoguesofcyclic
phosphatic acid (1-acyl-sn-glycero-2,3-cyclic-phosphate,
cPA) [42, 43]. The naturally occurring cPA, 1-oleoyl-sn-
glycero-2,3-cyclic-phosphate (cPA 18:1) possesses unique
properties having two targets: enzyme and receptor. cPA
18:1 inhibits ATX activity with a maximum of 22% at
1μM and inhibits signaling pathway mediated through LPA1
and LPA3 receptors. Because of this properties, cPA 18:1
is described as having a “one-two punch” [44]. Another
naturally occurring cPA, cPA 16:1 (1-palmitoleoyl-sn-
glycero-2,3-cyclic-phosphate) possesses similar activity
against ATX with maximum of 45% at 1μM.
Interestingly, replacement of either the sn-2 or sn-3
oxygen by methylene (carba group) increases the inhibitory
properties of these analogues (carba analogues, ccPA) [45].
2ccPA16:1and2cPA18:1(replacementofsn-2 oxygenwith
a methylene group) inhibit ATX activity about 90% with
IC50 ∼ 140nM and ∼370nM, respectively. Furthermore,
3ccPA 16:1 and 3ccPA 18:1 (replacement of sn-3 oxygen
with methylene group) inhibit ATX activity about 70% with
IC50 ∼ 300nM and ∼60nM, respectively. Moreover, 3ccPA
does not interact with LPA receptors. The invasion assay
using melanoma cells (A2058) has provided evidence that
ccPA-induced inhibition of ATX activity results in inhibition
of cell migration. Furthermore, cPA and ccPA exert an
inhibitory eﬀect on experimental pulmonary metastasis in
mice. Recently, a new generation of ccPA with potential
therapeutic modality has been developed. Thio-ccPA 18:1
possesses multitarget properties. It inhibits ATX activity
(∼90% at 10μM) and blocks LPA1 (IC50 ∼ 800nM)
and LPA3 (IC50 ∼ 440nM) receptors without eﬀect on
LPA2 receptors. Thio-ccPA inﬂuences metastatic melanoma
tumors in vivo, reducing the number of pulmonary metas-
tases and metastatic lesions to kidney, liver, pancreas, and
intestines [32].
4.3. Nonlipid Small Molecule. It has been recently shown
that thiazolidinediones compounds with incorporated boric
acid moiety into catalic T210 residue (HA 130) inhibit
ATX-mediated LPA production with IC50 ∼ 30nM [46].
Intravenous injection of HA 130 decreases 3.8-fold plasma
LPA level in mice at 10min. Furthermore, HA 130 inhibits
ATX-mediated melanoma cells migration without aﬀecting
LPA receptor signaling pathways.
A report has been recently published describing the
pharmacokinetic and pharmacodynamic properties of PF-
8380 [47]. It inhibits activity of isolated ATX or ATX activity
in blood with IC50 ∼ 3 and 100nM, respectively. There are
nodataaboutinﬂuenceonmelanoma cells,hoverer,PF-8380
(30mg/kg) takenorally decreases the plasma LPA levelabout
95%, suggesting its potential usage in melanoma treatment.
There are several small-molecule, nonlipid ATX inhibi-
tors including hexachlorophene, merbromin, bithionol, and
others under investigation [48, 49]. Their mechanism of
action diﬀer (competitive, noncompetitive or mixed inhibi-
tion) and the most potent compounds inhibit ATX activity
with IC50 at micromolar range. Their biological action
was conﬁrmed in experiments in vivo measuring eﬀects on
melanoma cell motility and invasion. A recently developed
new TX autotaxin inhibitor pipemidic acid inhibits ATX
with IC50 ∼ 900nM [50]. The natural phenolic antiox-
idants, including ﬂavonols, possess inhibitory properties
against ATX; however, the eﬀect on ATX activity is about
2-fold lower than LPA 16:1 (1-palmitoleoyl-sn-glycerol-3-
phosphate). Moreover, it has been estimated that it would
be diﬃcult to aﬀect ATX activity in vivo by ﬂavonoids
supplementation in diet because plasma concentration of
ﬂavonoids in plasma may reach 10μM[ 51].
The recently published crystallography results are used
in ligand-based computational approaches for optimization
of the current ATX inhibitors and development of new ones
[52, 53].
Taken together, the increasing incidence of melanoma
and poor average survival of metastatic melanoma are the
main reason for the development of the new chemical com-
pounds used in melanoma treatment. Autotaxin, melanoma
cell motility-stimulating factor, and their receptors seem
to be promising targets for pharmacological treatment4 Enzyme Research
of melanoma. Much more research is needed for synthesis
and pharmacologicalcharacterization ofnew speciﬁc ATXor
LPA receptors inhibitors.
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